Markets SVB Leerink starts Kalvista Pharma at OP; PT $31 SVB Leerink initiated coverage of Kalvista Pharmaceuticals (NASDAQ:KALV) with an “outperform” rating and $31 price target. The stock closed at $16.92 on July 26. Kalvista is creating a new generation of small molecule... July 29, 2019